Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2022 | Addition of carfilzomib as a third agent in lenalidomide-refractory patients with multiple myeloma

Claudio Cerchione • 10 Jun 2022
EHA 2022
Multiple Myeloma Carfilzomib Lenalidomide

Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses the benefit of adding carfilzomib as a third agent to lenalidomide-based doublet regimens in patients with multiple myeloma who are refractory to lenalidomide. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Claudio Cerchione

Updates on myeloma research from IMS 2025: advances in frontline and R/R treatment 4:27
Updates on myeloma research from IMS 2025: advances in frontline and R/R treatment
Claudio Cerchione • 18 Sep 2025
Performance of a novel prognostic index for multiple and smoldering myeloma 1:49
Performance of a novel prognostic index for multiple and smoldering myeloma
Claudio Cerchione • 18 Sep 2025
Looking forward to the upcoming MYELOMAS meeting in Rome, Italy 1:34
Looking forward to the upcoming MYELOMAS meeting in Rome, Italy
Claudio Cerchione • 18 Sep 2025
Isatuximab plus quadruplet regimens in transplant-eligible and transplant-ineligible myeloma 2:35
Isatuximab plus quadruplet regimens in transplant-eligible and transplant-ineligible myeloma
Claudio Cerchione • 18 Sep 2025

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals